Objective To observe the clinical effect of concentrate growth factors（CGF）in osteotome maxillary sinus elevation.Methods A total of 37 patient (47 implant sites)with insufficient residual bone height in the maxillary posterior region who were admitted in the Implant Center of Fujian Provincial Hospital from December 2019 to May 2021 were selected as the research subjects.They were divided into experimental group (20 cases,23 implant sites)and control group(17 cases,24 implant sites)according to random number table method.47 implants were implanted after osteotome maxillary sinus elevation.The experimental group was implanted with CGF in maxillary sinus,while the control group was implanted with Bio-oss bone graft materials.All patients were followed up immediately,6 and 12 months after operation to observe the clinical effects and imaging changes.Results Only one patient had implant loosening,and the survival rate was 97.9%.There were no significant differences in peri-implant bone height between the experimental group and the control group immediately,6 and 12 months after operation (P＞0.05).The experimental group and control group were divided into three groups according to the elevation height∶group 1(＜3 mm),group 2(3-4 mm),and group 3(＞4 mm).At 6 and 12 months after operation，there was no significant difference in sinus bone increment with different elevation height in experimental group(P＞0.05),and there was no significant difference between group 1 and group 2 in control group(P＞0.05).In control group,the increment of sinus bone in the groups 3 was higher than that in group 1 and group 2,and the differences were statistically significant (P＜0.05).Conclusion CGF alone in osteotome maxillary sinus elevation can achieve osteogenic effect similar to that of bone graft materials during the observation period.